report us cig volum e-cig stall
accord us cig industri volum end vs report nielsen best
print year last time us cig volum ere better august cig volum improv
happen oct hen altria increas price third time year notabl coincid ith e-cig yoy sale grow th
drop first print last year
 ritten extens primari caus us cig volum eak last year exponenti e-cig grow th
e-cig stall cig volum ill improv back histor averag bear point reason
cannabi afford consum health-consci oil price excis tax hike etc think subsequ
print ill establish valid thesi
inde juli rote second deriv us cig volum ill posit till end smoke
signal second deriv us volum turn posit atermelon blueberri happen
happen juul stop sell mint announc last eek trump administr announc flavor e-cig
ban expect time consid pmta deadlin may think e-cig take leg dow
end us cig industri volum accord middl comp
easi think investor surpris see strong us cig volum
august altria stock trade pe bat stock trade pe current stock trade
singl digit pe think bat particular long ay go financi leverag ill magnifi equiti move
bat vuse highest grow th amongst e-cig month exposur tobacco menthol e-cig
sale significantli under-index youth compar closed-tank e-cig base youth survey data
zyn report share increment grow th modern oral categori track achiev can line
 ith estim
us cigarett volum declin eek end novemb slightli ors eek end octob
note nielsen rectifi measur issu us tobacco data still overst volum declin hen
compar msai data
us volum declin altria bat imb ere respect ever coincid ith price increas
octob
 think e-cig like take knock juul announc ill stop sell mint flavor last eek mint juul
sale juul new ceo place sinc sep rebas juul busi prepar pmta process view fda
final draft guidanc ban e-cig flavor next day expens pmta process lead shake e-
cig industri continu vapi epidem lead consum step aw ay e-cig albeit temporarili view
 note altria guid us cigarett volum declin bat expect industri volum declin
altria long-term guidanc
close tank e-cig industri sale dow slightli month-on-month basi ith eek end novemb data indic
declin eek end octob yoy basi e-cig grew low estimate grow th rate year
fda ork tow ard ban flavor e-cig base recent comment appear menthol e-cig ill
ban flavor ill notabl non-tobacco menthol flavor account juul sale njoy
juul sale dow sequenti note juul recent appoint crosthw ait ceo ho svp chief
strategi grow th offic altria believ juul sale could declin also note juul ban sale
mint-flavor pod us last eek juul privat entiti altria passiv invest stake juul
njoy e-cig sale dow sequenti refil eek end novemb njoy
sale blueberri atermelon tw ist flavor njoy control big tobacco compani
bat e-cig sale ere sequenti ere eek end novemb imb e-cig sale declin
zyn sale continu grow sequenti sale grow th eek end octob
zyn continu sequenti grow th next month sw ill like sell can per
nielsen model sw volum current grow ing quarter-on-quart think sw manag might soon
need expand capac plan current annual capac
zyn share increment grow th modern oral categori month-over-month hile altria velo bat
ramp combin increment sale grow th
us cigar volum declin eek end novemb slightli better eek end octob
notabl altria cigar volum ere eek end novemb altria comment earn call
doesnt expect propos flavor cigar ban impact cigar busi portfolio grandfath
receiv market order altria cigar busi asnt boom last year hen sw imb cigar busi
might better protect
cigar industri might structur declin due lack innov post deem date august
recreat marijuana legal sever us state result avail better form factor vape devic pax
 upcom flavor cigar ban expect time fda final draft guidanc pmta deadlin may
zyn sale continu grow sequenti
barclay research nielsen data data
wintergreen mint flavor domin zyn sale
zyn report share increment growth modern oral categori
menthol tobacco flavor account juul sale
menthol tobacco flavor account njoy sale
summari latest nielsen data us cigar volum declin
barclay research nielsen data data
juul sequenti sale
barclay research nielsen data data
bloomberg data close
bloomberg data close
bloomberg data close
tobacco-rel item hhs/fda spring agenda
offic inform regulatori affair
imperi brand plc new chairperson dividend stabil still grow ing ep support stock
bat pmi fda reportedli could announc e-cig flavor ban eek
british american tobacco plc meet ith cfo
inc long journey rebuild trust
japan tobacco guidanc low ere due eak rrp roll-out oct
global tobacco juul uk europ financi oct
sw edish match zyn off-set flavor cigar oe pt sek oct
european consum stapl vape epidem fallaci e-cig flavour ban oct
european consum stapl earn preview cut altria pt oct
imperi brand plc back ebit grow th compani sep
pm-mo ill merger back sep
european consum stapl dank vape youth tobacco survey forc fda hand sep
confer feedback tilray cover sep
confer feedback cover sep
confer feedback crono group cover sep
european consum stapl pm-mo chang exchang ratio aug
british american tobacco plc fx emerg major tailw ind august
japan tobacco inc problem home august
sw edish match zyn larg off-set cigar oe juli
replay confer call audio transcript confer call ith mr ill oodle kkb llp recent
evolut tobacco cannabi regul juli
altria/bat us nielsen data juul slow dow zyn continu grow steadili us cig volum improv juli
global stapl pictur juli
inc iqo back track upgrad ow juli
 british american tobacco ill earli pmta deadlin deem product impact e-cig grow th juli
european consum stapl smoke signal second deriv us volum turn posit atermelon blueberri
imperi brand announc opportunist share buy-back juli
activist ex-regul suggest juul/clos tank get regul over-the-counter drug june
fda cig nicotin reduct rulemak move glacial pace jun
pm fda author market iqo us cig reduc risk author still aw ait may
smoke signal flavor ban ork evid us e-cig data feb
mentholet analys possibl implic menthol ban dec
smoke signal kick tyre ith juul sep
smoke signal juul disrupt come tobacco juli
imperi brand initi heat burn dow may
gaurav jain herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill directli
indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
research report prepar hole part equiti research analyst base outsid us ho
registered/qualifi research analyst ith finra
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
research analyst employ outsid us affili barclay capit inc registered/qualifi research analyst
 ith finra non-u research analyst may associ person barclay capit inc hich finra member
therefor may subject finra rule restrict commun ith subject compani public appear
trade secur held research analyst account
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog set price target altria base price-to-earnings valuat last tw decad altria trade
averag fw multipl higher cigarett volum declin regulatori uncertainti manag attempt sell us
busi p/core tobacco ep expect pressur multipl near-term valu altria price-to-earnings add
addit valu per share juul crono get price target usd
risk may imped achiev barclay research valuat price target fda regul drastic
rate price target histori
prior intra-day chang may publish rate price target secur ere
histor stock price price target may adjust stock split dividend
valuat methodolog consid british american tobacco valuat use three differ approach p/e-
base approach irr-bas approach part sotp set price target base approach
appli multipl ep result hich round
risk may imped achiev barclay research valuat price target regulatori agenda
fda ill domin headlin everi month like creat period heighten volatil altria aggress ith
iqo could lead signific up-front invest disrupt market share equilibrium damag market profit
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc bloomberg reflect close price relev trade market hich
may last avail price time public
